0000000000454942

AUTHOR

Dieter F. Braus

showing 5 related works from this author

Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial

2015

Patients with Major Depressive Disorder (MDD) and no improvement after two weeks of antidepressant pharmacotherapy have a high risk of treatment failure. The aim of the study was to determine whether an early medication change (EMC) strategy is superior to a guideline-based treatment in MDD patients without improvement after two weeks of antidepressant pharmacotherapy. Eight-hundred-and-eighty-nine patients with MDD were enrolled, 879 patients received the SSRI escitalopram. Of those, 192 patients had no improvement, defined as a reduction of < 20% on the Hamilton Depression Rating Scale (HAMD-17) after 14 days of treatment, and were randomly assigned to open treatment with the EMC strategy…

AdultMalemedicine.medical_specialtyAdolescentCitalopramLithiumCitalopramlaw.inventionDepressive Disorder Treatment-ResistantYoung Adult03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled triallawEarly Medical InterventionInternal medicinemedicineHumansEscitalopramPharmacology (medical)PsychiatryBiological PsychiatryAgedPharmacologyVenlafaxine HydrochlorideGuidelineMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryClinical trialPsychiatry and Mental healthTreatment OutcomeNeurologyDelayed-Action PreparationsAntidepressive Agents Second-GenerationAntidepressantMajor depressive disorderDrug Therapy CombinationFemaleNeurology (clinical)Psychology030217 neurology & neurosurgerymedicine.drugEuropean Neuropsychopharmacology
researchProduct

W05-01 - Rationale and Design of an RCT Comparing “EMC-Strategy” with TAU in Patients with Major Depression - the EMC Trial

2010

IntroductionFor Major Depression, current guidelines recommend treatment durations of 3-8 weeks until optimisation in case of insufficient outcome. Many retrospective studies indicate that improvement (HAMD-17 decrease ≥20%) occurs usually within 10-14 days and that non-improvement after 14 days of treatment is highly predictive for poor clinical outcome.MethodsIn level 1 of the EMC trial, non-improvers after 14 days of antidepressant treatment will be randomised to “early medication change” (EMC) strategy or treatment according to current guidelines (TAU). EMC schedules treatment optimisations on day 15 and day 29 in case of non-improvement. TAU schedules a medication change after 28 days …

medicine.medical_specialtyPediatricsbusiness.industryRetrospective cohort studylaw.inventionMedication changeClinical PracticePsychiatry and Mental healthRandomized controlled triallawMedicineIn patientbusinessPsychiatryDepression (differential diagnoses)European Psychiatry
researchProduct

Neural correlates of working memory dysfunction in first-episode schizophrenia patients: an fMRI multi-center study.

2005

Working memory dysfunction is a prominent impairment in patients with schizophrenia. Our aim was to determine cerebral dysfunctions by means of functional magnetic resonance imaging (fMRI) in a large sample of first-episode schizophrenia patients during a working memory task. 75 first-episode schizophrenia patients and 81 control subjects, recruited within a multi-center study, performed 2- and 0-back tasks while brain activation was measured with fMRI. In order to guarantee comparability between data quality from different scanners, we developed and adopted a standardized, fully automated quality assurance of scanner hard- and software as well as a measure for in vivo data quality. After t…

AdultMaleVentrolateral prefrontal cortexAdolescentPrecuneusPrefrontal CortexSerial LearningTemporal lobeThalamusReference ValuesmedicineImage Processing Computer-AssistedReaction TimeHumansAttentionPrefrontal cortexBiological PsychiatryTemporal cortexn-backBrain Mappingmedicine.diagnostic_testWorking memoryMiddle AgedMagnetic Resonance ImagingTemporal LobePsychiatry and Mental healthmedicine.anatomical_structureMemory Short-TermPattern Recognition VisualSchizophreniaFemaleNerve NetPsychologyFunctional magnetic resonance imagingNeuroscienceSchizophrenia research
researchProduct

Net influx of plasma 6-[18F]fluoro-L-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli.

2006

Dopaminergic neurotransmission in the ventral and dorsal striatum interact with central processing of rewarding and reward-indicating stimuli, and may affect frontocortical-striatal-thalamic circuits regulating goal-directed behaviour. Thirteen healthy male volunteers were investigated with multimodal imaging, using the radioligand 6-[ 18 F]fluoro-L-DOPA (FDOPA) for positron emission tomography (PET) measurements of dopamine synthesis capacity, and also functional magnetic resonance imaging (fMRI) in a cognitive activation paradigm. We calculated the correlation between FDOPA net blood-brain influx (K app in ; ml/g/min) in the ventral and associative dorsal striatum and BOLD signal changes …

AdultMaleFluorine RadioisotopesDopaminePrefrontal CortexStriatumNucleus accumbensSynaptic TransmissionReward systemmedicineHumansOperculum (brain)Anterior cingulate cortexmedicine.diagnostic_testGeneral NeuroscienceVentral striatumPutamenMiddle AgedMagnetic Resonance ImagingCorpus StriatumDihydroxyphenylalanineDorsolateral prefrontal cortexAffectmedicine.anatomical_structurenervous systemPositron-Emission TomographyCaudate NucleusRadiopharmaceuticalsFunctional magnetic resonance imagingPsychologyNeurosciencepsychological phenomena and processesPhotic StimulationThe European journal of neuroscience
researchProduct

Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with Major Depressive Disorder

2017

Executive dysfunctions frequently occur in patients with Major Depressive Disorder and have been shown to improve during effective antidepressant treatment. However, the time course of improvement and its relationship to treatment outcome is unknown. The aim of the study was to assess the test performance and clinical outcome by repetitive assessments of executive test procedures during antidepressant treatment. Executive test performance was assessed in 209 –patients with Major Depressive Disorder (mean age 39.3 ± 11.4 years) and 84 healthy controls five times in biweekly intervals from baseline to week 8. Patients were treated by a defined treatment algorithm within the early medication c…

Malelcsh:MedicineSocial SciencesNeuropsychological TestsSeverity of Illness IndexExecutive FunctionCognition0302 clinical medicineMedicine and Health SciencesPsychologyVerbal fluency testlcsh:ScienceProspective cohort studyDepression (differential diagnoses)Cognitive ImpairmentMultidisciplinaryDepressionCognitive NeurologyPharmaceuticsCognitive flexibilityDrugsCognitionAntidepressantsMiddle AgedAntidepressive AgentsCognitive LinguisticsChemistryTreatment OutcomeNeurologyPhysical SciencesMajor depressive disorderFemaleResearch ArticleChemical ElementsAdultmedicine.medical_specialtyCognitive NeuroscienceLithium03 medical and health sciencesDrug TherapyNeuropsychologyRating scaleMental Health and PsychiatrySeverity of illnessmedicineHumansNeuropsychological TestingPharmacologyDepressive Disorder MajorMood Disordersbusiness.industrylcsh:RBiology and Life SciencesLinguisticsmedicine.disease030227 psychiatryCase-Control StudiesPhysical therapyCognitive Sciencelcsh:QbusinessPsychomotor Performance030217 neurology & neurosurgeryNeurosciencePLOS ONE
researchProduct